Discovery of 5α-pregnan-2β,3α-diol-20-one as a neuroHIV Protective Agent by Khan, Md Imdadul H. et al.
University of Mississippi 
eGrove 
Annual Poster Session 2021 Annual Poster Session 
10-19-2021 
Discovery of 5α-pregnan-2β,3α-diol-20-one as a neuroHIV 
Protective Agent 
Md Imdadul H. Khan 
University of Mississippi, mkhan4@go.olemiss.edu 
Mohammed F. Salahuddin 
University of Mississippi 
Nicholas S. Akins 
University of Mississippi 
Fakhri Mahdi 
University of Mississippi 
Seong Jong Kim 
United States. Department of Agriculture 
See next page for additional authors 
Follow this and additional works at: https://egrove.olemiss.edu/pharm_annual_posters_2021 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Khan, Md Imdadul H.; Salahuddin, Mohammed F.; Akins, Nicholas S.; Mahdi, Fakhri; Kim, Seong Jong; Li, 
Jing; Paris, Jason J.; and Le, Hoang V., "Discovery of 5α-pregnan-2β,3α-diol-20-one as a neuroHIV 
Protective Agent" (2021). Annual Poster Session 2021. 10. 
https://egrove.olemiss.edu/pharm_annual_posters_2021/10 
This Book is brought to you for free and open access by the Annual Poster Session at eGrove. It has been accepted 
for inclusion in Annual Poster Session 2021 by an authorized administrator of eGrove. For more information, please 
contact egrove@olemiss.edu. 
Authors 
Md Imdadul H. Khan, Mohammed F. Salahuddin, Nicholas S. Akins, Fakhri Mahdi, Seong Jong Kim, Jing Li, 
Jason J. Paris, and Hoang V. Le 
This book is available at eGrove: https://egrove.olemiss.edu/pharm_annual_posters_2021/10 
Discovery of 5α-pregnan-2β,3α-diol-20-one as a neuroHIV Protective Agent  
Md Imdadul H. Khan,1,† Mohammed F. Salahuddin,1,† Nicholas S. Akins,1,† Fakhri Mahdi,1 Seong Jong Kim,2 Jing Li,1 Jason J. Paris,1,* Hoang V. Le1,* 
, 
1Department of BioMolecular Sciences and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, Mississippi 38677, USA 
2Natural Products Utilization Research Unit, United States Department of Agriculture, Agricultural Research Service, University, Mississippi 38677, U.S.A 
 
 Currently, about 1.2 million people are suffering from HIV in the U.S. 
 Combined antiretroviral therapeutics (cART) can eradicate circulatory 
viral load of HIV and have extended the lives of HIV-1 infected 
individuals. 
 About half of HIV-1 patients suffer from affective and cognitive 
neurological symptoms (called “neuroHIV”). 
 Neurotoxic viral proteins such as the trans-activator of transcription 
(Tat), and glycoprotein 120 (gp120), are thought to be present in the 
central nervous system and contribute to neuroHIV which cannot be 
eradicated by cART. 
 Tat can disrupt ion homeostasis through activation of NMDA receptors 
and Ca2+ channels.  
 Ion dysregulation and mitochondrial stress result in translocation of pro-
apoptotic Bax, cyt c and cause neuronal damage or death.  
 As a result, Tat promotes cognitive and affective dysfunction in mice. 
HIV Neurotoxicity   
Neuroprotective Agents against HIV-Tat 
Protein   
Neurotoxic Viral Proteins   
Our Goal 
Results Discussion 
HIV-1 Tat and/or gp120 
produced necrosis of 
mouse primary medium 
spiny neurons in mixed 
glial co-culture following 
20 h (see *). 
Pretreatment with 3α,5α-
THP (panel A) or 
compound 1 (panel B) 
significantly attenuated 
necrosis at every dose 
assessed (see †). The 
highest concentrations of 
either compound 
increased baseline cell 
death modestly (see ^), 
but were still protective, p 
< 0.05.  
3α,5α-THP Analogues 
Synthetic Scheme 
 Using structure based drug discovery approach, we designed 
analogues through stereospecific functionalization at C2 position of 
3α,5α-THP (allopregnanolone).   
 Our hypothesis is our designed compounds will ameliorate the viremia, 
inflammation, and neurotoxicity caused by infectious HIV-1 both in vitro 
and in vivo animal model.  
 Preliminary results of in vitro showed that stereospecific modification at 
C2 position of 3α,5α-THP is crucial for activity.  
 Currently we are working on a library of potential compounds having 
good PK profile, complement cART, and potent against neuroHIV 
symptomatology.    
Allopregnanolone or 
compound 1 attenuates 
HIV-1BaL (1 ng/mL p24) 
replication over 10 days 
as indicated by the 
accumulation of p24 HIV 
capsid protein. Neither 
allopregnanolone nor 
compound 1 impair the 
efficacy of cART when co-
administered.  
 As a proof-of-concept, compound 1 showed protection against HIV 
neurotoxicity and viremia.  
 Both allopregnanolone and compound 1 showed inhibition of Cav1.1 
channel and modulation of GABAA receptor. 
 Compound 2 did not show good activity suggested the importance of 
stereospecific functionalization of 3α,5α-THP.   
 Further computational investigation showed that unlike compound 2, 
compound 1 has good binding interaction in α1-β3 intersubunit site of 
GABAA receptor. MD simulation also confirmed the stability of the 
binding interaction.    
 Currently, we are investigating PK profile and in vivo efficacy of 
compound 1 in anxiety-like behavior, depression-like behavior, 
cognition and motor function of HIV-1 Tat expressing transgenic mice 
model.  
Phytoestrogens Steroids 
Conclusion & Future Plan 
 Compound 1 showed protection against neuroHIV. 
 We will assess compounds 3-8 in in vitro model.  
 Pharmacokinetics, cART interaction, and neuroHIV symptomatology 
studies of 1 are being carried out in in vivo model. 
A. Overlaid structure of compound 
1 and α1-β3 intersubunit site of 
GABAA R (PDB ID 6I53). B. RMSD 
of compound 1 and side chains of 
the binding residues in MD 
simulation 
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